George Eric Davis - 29 Apr 2022 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
EVP, Chief Legal Officer
Signature
/s/ Eric Fleekop, Attorney-in-Fact
Issuer symbol
BMRN
Transactions as of
29 Apr 2022
Net transactions value
-$637,412
Form type
4
Filing time
04 May 2022, 12:01:01 UTC
Previous filing
27 Apr 2022
Next filing
11 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Award $21,281 +341 +0.52% $62.41 66,339 29 Apr 2022 Direct F1
transaction BMRN Common Stock Options Exercise $574,899 +15,347 +23% $37.46 81,686 02 May 2022 Direct F2
transaction BMRN Common Stock Sale $1,233,592 -15,347 -19% $80.38 66,339 02 May 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -15,347 -100% $0.000000* 0 02 May 2022 Common Stock 15,347 $37.46 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired by the reporting person on April 29, 2022, pursuant to the issuer's Employee Stock Purchase Plan.
F2 Trade made pursuant to a 10b5-1 plan executed on March 4, 2022.
F3 Reflects the number of options outstanding after the transactions from this specific stock option grant.